

12

EUROPEAN PATENT APPLICATION

21 Application number: 86113038.3

27 Date of filing: 22.09.86

51 Int. Cl.⁴: C 07 C 177/00
 //C07C101/04, C07C101/12,
 C07C103/46, C07D295/14,
 C07C149/243, A61K31/557

30 Priority: 04.10.85 IT 2235885

43 Date of publication of application:
 22.04.87 Bulletin 87/17

84 Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE


71 Applicant: IBI-Istituto Biochimico Italiano Giovanni
 Lorenzini S.p.A.
 Via Lorenzini 2-4
 Milan(IT)

72 Inventor: Valcavi, Umberto
 Via degli Anemoni 21
 Milan(IT)

74 Representative: Klausner, Erich et al,
 c/o Ufficio Internazionale Brevetti Ing. C. Gregorj S.p.A.
 Via Dogana 1
 I-20123 Milano(IT)

54 Derivatives of 19,20-bis-nor-prostanoic acid with antiulcer and anorectic activity, process for their preparation and pharmaceutical compositions thereof.

57 Derivatives of 19,20-bis-nor-prostanoic acid of general formula (I)



(I)

or a pharmaceutically acceptable salt thereof, are described, having antiulcer activity or useful as appetite depressing agents, a process for their preparation and pharmaceutical compositions thereof.

- 1 -

1 DESCRIPTION OF THE INVENTION

The causes of peptic ulcer are not completely known. It does seem to be established, however, that there exists a balance between the factors which tend to promote ulceration, 5 such as excessive secretion of acid or pepsin, and those which protect the mucosa, such as mucus secretion and the rate of formation of new membrane cells.

Among the numerous therapies indicated for the treatment of peptic ulcer, the natural prostaglandins and, successively, 10 their analogues have been studied in this regard over the last decade.


Amongst the drugs belonging to this new class, and presently being processed for the market, are Misoprostol[®] (BE 827.127, DE-OS 2.513.212 to G.D.Searle & Co. Ill.) and 15 Rosaprostol[®] (IT 1.060.366 issued 10.07.1982 to the Applicants).

The Applicants had previously found that utilizing an

1 18 carbon atom skeleton and simplifying the structure of
PGE₁, it was possible to obtain in particular a drug (Rosapro-
stol^(R)) which, although maintaining the antiulcer properties
of the natural prostaglandins, completely loses the others.

5 Working on this new skeleton, it has now surprisingly
been found that the substitution of an amino group for the
oxygen at the 9 position yields the derivatives with antiulcer
activity distinctly superior to that of the parent compound
Rosaprostol^(R) (viz. 9-hydroxy-19,20-bis-nor-prostanoic acid
10 sodium salt) from which they derive.

These new compounds correspond to the following formu-
la(I)



wherein :

R and R' can be the same or different and each represents H,
a linear or branched alkyl, alkenyl, alkynyl, (C₁-C₅)-acyl
group, -CH₂COOH, -SO₂NH₂, -COCH(NH₂)CH₂SH, or taken together,
20 a 3 to 8-membered ring, the members of which may be a carbon
atom or any one of the heteroatoms N, O, S.
X is hydroxy, a (C₁-C₅)-alkoxy, phenoxy, benzyloxy or a
-NHR" group (wherein R" is (C₁-C₅)-alkyl or H).

1 Y is $-\text{CH}_2$, $\overset{|}{\text{CH}}-\text{CH}_3$, O, S, $=\text{NH}$, $-\text{NCH}_3$.

Compounds of the general formula (I) wherein $\text{Y}=\text{CH}_2$, $\text{R} = \text{H}$,
and $\text{R}' = \text{H}$, (C_1-C_4) -alkyl are the subject matter of IT 1060366
(of the Applicants) in which their activity as hypolipaemics,
5 inhibitors or platelet aggregation and hepatic protectors is
disclosed. For that reason they are not claimed per se in the
present patent, whereas their therapeutic use as appetite de-
pressors and antiulcer agents is claimed herewith.

The invention includes also the pharmaceutically accept-
10 able cationic salts of the compounds of formula (I), when
 $\text{X} = \text{OH}$, and in general all the pharmaceutically acceptable
anionic salts.

The expression "pharmaceutically acceptable cationic
salts", as used herein, refers to salts with alkali or alka-
15 line earth metals such as, e.g. calcium, magnesium, sodium,
potassium or salts of aluminium, ammonia, zinc and of organic
amines such as, e.g. triethanolamine, and also amino acids,
such as lysine, arginine, phenylalanine and proline, internal
salts and salts of basic resins.


20 The expression "pharmaceutically acceptable anionic
salts", as used herein, refers to salts obtained by the addi-
tion of an inorganic acid, such as, e.g. hydrochloric, hydro-
bromic, nitric, phosphoric, sulphuric, or by the addition of
an organic acid such as, e.g. benzenesulphonic, benzoic,

1 citric, laurylsulphonic, fumaric, oxalic, maleic, methane-
sulphonic, tartaric, ascorbic, p-toluenesulphonic, sali-
cyclic or succinic. With polybasic acids the salt can be one
5 theless salts formed of one mole of acid per mole of product
are preferred.

The antiulcer activity of these derivatives was evaluated
on ulcers induced by the administration of ethanol, hydrochlo-
ric acid and sodium hydroxide in the rat, also on gastric
10 ulcers induced by aspirin in the rat, and on their influence
on gastric secretions in the rat.

The compounds can be prepared, e.g. according to the
following reaction schemes:

A) When $R = R' = H$ and Y is defined as hereabove. Starting
15 from the corresponding ketone, with hydroxylamine to
obtain the oxime of formula (III)




The oxime is then reduced with hydrogen to the desired
20 amines.

B) When R, R', X and Y have the meanings given for formula(I).

Starting from the corresponding ketone, through a reduc-
tive amination with $RR'NH$. The carboxylic group is then
transformed in the final ester-amide-acid and so on, ac-
cording to per se known methods.


1 The starting ketone can be obtained in two different ways.

C) When $Y = -CH_2$; $-CH-CH_3$; $-O-$. Starting from the cyclopentenone (VI) through an organo copper (II) reagent:



D) When $Y = NH$, NCH_3S .

According to the following scheme:



20 Reagents: $D_1 = IM_g \text{---} OCH_3$, CuI ; $D_2 = KOH$, $MeOH$; $D_3 = Me_3SiI$;
 $D_4 = R'''OH, H^+$; $D_5 = CH_3Y^\ominus$.

The pharmaceutically acceptable cationic salts of the compounds of the present invention are readily prepared by allowing the acidic form to react with the appropriate base, normally 1 equivalent, in a co-solvent. Suitable bases are,

1 e.g. :sodium hydroxide, sodium bicarbonate, sodium methoxide,
sodium ethoxide, sodium hydride, potassium hydroxide, magne-
sium hydroxide, calcium hydroxide and so on.

Salts obtained by addition of acids are prepared by al-
5 lowing the free base to react with the appropriate organic
mineral acid (see above).

The examples and compounds given here below are only il-
lustrative of the invention and shall not be construed restric-
tively. The activity of the inventive compounds as antiulcer
10 agents was determined by the following series of tests.

1) Ethanol induced ulcers in the rat:

The method used is that described by A. Robert et al, in
Gastroenterology 77,433 (1979), the disclosure of which
is incorporated herein by reference.

15

20










TABLE 1 : Percent inhibition of ethanol induced ulcers
in the rat.







Compound Code	D O S E :mg/kg					
	100	50	25	10	5	2.5
 NH ₂ IBI-O-01009	N.D.	88%	67%	70%	50%	40%
 NHCH ₃ IBI-P-01013	91%	91%	86%	67%	44%	N.D.
 N- IBI-P-01014	91%	97%	N.D.	62%	43%	24%
 NH- IBI-P-01015	N.D.	65%	34%	9%	N.D.	N.D.
 NHCOCH ₃ IBI-P-01012	78%	N.D.	N.D.	25%	N.D.	N.D.
 OH Rosaprostol	37%	9%	N.D.	N.D.	N.D.	N.D.

N.D. Not determined.

1 2) Hydrochloric acid induced ulcers in the rat:

The method used for this test is that described by A. Robert et al, in Gastroenterology, 77,433, (1979), the disclosure of which is incorporated herein by reference.

5 TABLE 2: Percent inhibition of Hcl induced ulcers in the rat.







Compound Code	D O S E mg/kg			
	200	100	50	25
<div>  IBI-O-01009 </div>	91%	89%	68%	N.D.
<div>  IBI-P-01013 </div>	N.D.	66%	49%	40%
<div>  IBI-P-01014 </div>	N.D.	63%	55%	23%
<div>  IBI-P-01015 </div>	N.D.	54%	46%	0%
<div>  IBI-P-01012 </div>	N.D.	N.D.	66%	15%
<div>  Rosaprostol </div>	63%	45%	N.D.	15%

N.D. = Not determined

1 3) Sodium hydroxide induced ulcers in the rat:

Also this test is performed in accordance with the method described by A. Robert et al, in Gastroenterology, 77, 433 (1979), the disclosure of which is incorporated herein by reference.

5 TABLE 3: Percent inhibition of NaOH induced ulcers in the rat.

Compound Code	D O S E mg/kg						
	200	100	50	25	12.5	10	5
 IBI-O-01009	N.D.	N.D.	N.D.	80%	N.D.	54%	37%
 IBI-P-01013	N.D.	N.D.	N.D.	87%	81%	N.D.	N.D.
 IBI-P-01014	N.D.	N.D.	74%	63%	52%	N.D.	N.D.
 IBI-P-01015	N.D.	N.D.	54%	46%	13%	N.D.	N.D.
 IBI-P-01012	N.D.	N.D.	59%	19%	7%	N.D.	N.D.
 Rosaprostol	92%	84%	53%	//	//	//	//

N.D. Not determined.

1 4) Aspirin induced gastric ulcers in the rat:







For carrying out this test, the method described by
H.A.Carmichael, L.M.Nelson, R.I.Russel in Gastroenterology
74, 1229 (1978) is used, the disclosure of which is incor-
5 porated herein by reference.

TABLE 4: Percent inhibition of aspirin-induced ulcers in the
rat.

10

15

20

Compound Code	% inhibition at a dose of 200 mg/kg of drug
 NH ₂ IBI-O-01009	72%
 NHCH ₃ IBI-P-01013	87%
 N IBI-P-01014	88%
 NH IBI-P-01015	63%
 NHCOCH ₃ IBI-P-01012	58%
 OH Rosaprostol	64%







1 5) Gastric secretion in the rat:

Sprague-Dawley rats of both sexes are used for this test.

The gastric secretion is rated according to the method described by H. Shay et al in Gastroenterology 5,43 (1945)

5 the disclosure of which is incorporated herein by reference.

TABLE 5: Percent inhibition of gastric secretion in the rat
2 and 4 hours after treatment

Compound Code	D O S E mg/kg							
	100		50		25		12.5	
	2h	4h	2h	4h	2h	4h	2h	4h
<div>10</div>  NH ₂ COOH IBI-0-01009	77%	89%	88%	68%	87%	N.D.	38%	N.D.
 NHCH ₃ COONa IBI-P-01013	79%	66%	54%	49%	0%	40%	N.D.	N.D.
<div>15</div>  N COONa IBI-P-01014	82%	63%	75%	55%	74%	23%	N.D.	N.D.
 NH COONa IBI-P-01015	37%	54%	56%	46%	35%	0%	N.D.	N.D.
<div>20</div>  NHCOCH ₃ COONa IBI-P-01012	70%	59%	48%	12%	51%	0%	N.D.	N.D.
 OH COONa Rosaprostol	50%	45%	30%	N.D.	0%	15%	N.D.	N.D.

N.D. Not determined.

1 The activity of the compounds object of the instant in-
vention in the here reported tests unfolds on two different
levels: on the one hand there is a cytoprotection of the gas-
tric mucosa against lesion-causing agents, such as ethanol,
5 which act directly, or such as aspirin, which act indirectly.
On the other hand, there is partial inhibition of acid secre-
tion which thus favours the cicatrizing process of the mucosa.
Such activity reflects the utility of these drugs in the
treatment of peptic ulcers in mammals including man.

10 These compounds should preferably be administered as a
pharmaceutical composition in admixture with one or more
pharmaceutically acceptable diluents and/or excipients. They
are preferably administered orally (for example as tablets,
granules, syrups, etc.) or parenterally (i.v. or i.m.).

15 Although the dose required will vary according to the symp-
toms, sex, weight and condition of the patient, and also ac-
cording to the frequency and route of administration, for
the purpose of this patent the compounds according to the
present invention can be administered to an adult in a daily
20 dosage of from 0.1 to 1500 mg, preferably of from 1 to 1000
mg in a single dosage or in subdivided dosages over a period
of 24 hours.

 The excipients for the pharmaceutical compositions for
oral administration are those usually employed by the phar-

1 maceutical industry for making tablets, granules or syrups,
such as, e.g. starch, lactose, Aerosil⁽¹⁾, magnesium stearate,
talc, glycine, sodium carbonate, polyethylene glycol, glucose,
saccharose, carboxymethylcellulose, natural flavourings, poly-
5 sorbates, pharmacoat, and so on.

Moreover, the compounds of the instant invention can be
employed as anorectics. It has in fact been found and it is
claimed herein that the subject compounds, at appropriate
dosages, slow down the rate of gastric depletion, thus depres-
10 sing the appetite, not by an effect on the central nervous
system, as is normally the case with other known anorectics,
but via a mechanism which, although not completely clear, ap-
pears to be more natural and completely new.

This second pharmaceutical activity is assessed through
15 the following test.

Gastric depletion in the rat.

Rats of both sexes and mean weight of 180-200 g are
used. The animals are subjected to fasting for 24 hours but
have free access to water up to 3 hours prior to the test.

20 Experimental scheme:

time	0 : drug or solvent
"	+30' : phenyl red
"	+50' : sacrifice.

25 (1) Aerosil is a brand of colloidal silicon dioxide, made by
Degussa, U.K.

- 1 Preparation of phenyl red solution: 50 mg of phenyl red is added with 100 ml of a 1.5% methyl cellulose solution and shaken for 5 hours.

1.5 ml per rat is administered irrespective of weight.

5 Methodology:

The rats are sacrificed by cervix translocation: the stomach is taken out after ligaturing the cardias and pilorus.

The entire stomach and contents are placed in the container of a homogenizer with 50 ml 0.1 N NaOH. They are homogenized for 2 minutes at a maximum velocity. The homogenate is transferred to a test-tube and left to settle for one hour.

5 ml of the supernatant is taken out and put into a centrifuge tube and added with 0.5 ml of 20%(w/v) trichloroacetic acid. The tube is centrifuged at 2500 rpm for 20 min. The entire supernatant is taken and added with 4 ml of 0.4N NaOH, and its absorbance is measured at 560λ.

Gastric depletion is calculated according to the following formula:

$$\left(1 - \frac{\text{sample absorbance}}{\text{standard absorbance}} \right) \times 100$$

20 As "standard absorbance" is considered the mean value of spectrophotometric measurement of 4 animals sacrificed immediately after administering phenyl red.

Table 6 summarizes the inhibition values of gastric depletion.






1

T A B L E 6

5

10

15

Compound Code	D O S E mg/kg		
	100	50	25
 NH ₂ IBI-O-01009	80%	80%	18%
 NHCH ₃ IBI-P-01013	N.D.	33%	N.D.
 N IBI-P-01014	N.D.	55%	N.D.
 NH IBI-P-01015	N.D.	14%	N.D.
 NHC(=O)CH ₃ IBI-P-01012	N.D.	78%	N.D.

N.D. Not determined.

EXAMPLE 1

9-hydroxyimino-19,20-bis-nor-prostanoic acid of formula (III)

wherein R''' = H and Y = -CH₂-

20

A solution of 9-keto-19,20-bis-nor-prostanoic acid of formula (II) wherein R''' = H and Y = CH₂, (196.5 g) in methanol (2.3 l) at room temperature, is added, over 20 min., with a solution of sodium acetate (300 g) and hydroxylamine hydro-

chloride (240 g) dissolved in water (2.3 l) and in methanol (2.3 l). The reaction mixture is kept 4 hours at room temperature under stirring. The methanol is evaporated at 50°C using a pulsor, the residue is taken up with methylene chloride (2 l) and separated.

The aqueous phase is extracted with more methylene chloride (500 ml). The combined organic phases are washed with water (1 l), dried and evaporated yielding a crude product (200.5 g) which is crystallized from pentane (400 ml) and ethyl ether (200 ml).

The crystallized product (110 g) has a m.p. of 51-52°C.

EXAMPLE 2

9-amino-19,20-bis-nor-prostanoic acid of formula (I) wherein

$R = R' = H$, $Y = -CH_2$, $X = OH$ (Compound IBI-P-01009).

A solution of the oxime (200 g) obtained in Example 1, in methanol (2 l), is added with platinum oxide (10 g).

The thus prepared mixture is put in a glass vessel under hydrogen (hydrogen pressure approx. 1 atm.) and stirred; then the reaction mixture is filtered and the solvent is evaporated.

The crude product (202.5 g) is washed with ethyl ether (4 l), suspended in acetone (250 ml), and filtered, yielding the pure title compound (82.5 g), m.p. 159-160°C.

1	<u>Elemental analysis</u>	<u>Calculated</u>	<u>Found</u>
	C	72.67%	72.81%
	H	11.86%	11.72%
	N	4.71%	4.75%

EXAMPLE 3

- 5 Sodium salt of 9-methylamino-19,20-bis-nor-prostanoic acid of formula (I) wherein $R = H$, $R' = CH_3$, $Y = CH_2$, $X = ONa$ (Compound IBI-P-01013).

A solution of the methyl ester of 9-keto-19,20-bis-nor-prostanoic acid of formula (II), wherein $R''' = Me$ and $Y = CH_2$,
 10 (31 g) dissolved in ethanol (20 ml), is added with a 2.5% solution of methylamine in ethanol (10 ml) and platinum oxide (0.1 g).

The mixture is stirred overnight at 50°C under hydrogen (pressure : 2 atm).

- 15 The reaction mixture is then cooled to ambient temperature, filtered off and evaporated under reduced pressure. The oily residue is taken up with 0.5M HCl (500 ml) and extracted with hexane (2 x 200 ml).

The organic phase is combined, dried and dessicated. The
 20 unmodified starting material is recovered (13.2 g). The acid aqueous phase is adjusted to pH 8 with bicarbonate, extracted with methylene chloride (3 x 200 ml). The combined organic phases are dried and evaporated under reduced pressure.

The residue is suspended in a solution of 1M NaOH(100ml), heated to 70°C and stirred until a clear solution results (2-3 hours). The solution is cooled to ambient temperature, acidified to pH = 5 and then extracted with methylene chloride (2 x 100 ml). The combined, dried organic phases are evaporated. The residue is taken up with tetrahydrofuran (40 ml), treated with 2 equivalents of a 1 molar solution of NaHCO₃ and dessicated. The dessicated mixture is taken up with methylene chloride (200 ml), filtered off and dessicated to yield the desired product (15.7 g).

Analysis (performed on the free acid): IR (ν_{\max} , cm⁻¹): 2920, 2860, 1710 ¹H-NMR(CDCl₃) δ : 9.5 (s, 1H); 2.9 (m, 1H); 2.4 (s, 3H), 2.2 (t, 2H); 1.3 (broad s, 26H); 0.9 (t, 3H).

EXAMPLE 4

Sodium salt of 9-dimethylamino-19,20-bis-nor-prostanoic acid of formula (I) wherein R = R' = CH₃, Y = CH₂, X = ONa.
(Compound IBI-P-01014).

It is proceeded as in Example 3, using the same starting methyl ester and dimethylamine in ethanol (14.3 ml of a 5.6 molar solution) to yield after work-up the title product (11.3 g).

Analysis (formed on the free acid): IR (ν_{\max} , cm⁻¹): 2940 2860, 1710, ¹H-NMR: 10.8 (s, 1H); 2.4 (2s, 6H); 2.2 (t, 2H); 1.3 (broad s, 26H); 0.9 (t, 3H).

1 EXAMPLE 5

Sodium salt of 9-isopropylamino-19,20-bis-nor-prostanoic acid
of formula (I) wherein $R = H$, $R' = -CH(CH_3)_2$, $Y = CH_2$, $X = ONa$.
(Compound IBI-P-01015).

5 It is proceeded as in Example 3, using the same starting
 methyl ester (31 g) and isopropylamine (4.7 g) in ethanol
 (30 ml) to yield after work-up the title product (12.5 g).
Analysis (performed on the free acid): IR ($\bar{\nu}_{max}, cm^{-1}$): 2940,
 2860, 1710, 1H -NMR($CDCl_3$): 8.8 (s, 1H); 3.2 (m, 2H); 2.2 (m, 2H);
 10 1.3 (m, 32H); 0.9 (t, 3H).

EXAMPLE 6

Methyl ester of 9-keto-17-oxa-prostanoic acid of formula (II)
wherein $R'' = Me$ and $Y = O$.

A magnesium (13g) suspension in tetrahydrofuran (390 ml)
 15 containing a catalytic quantity of iodine (approx. 0.1 g) is
 added with (4-bromo-n-butyl)-methyl ether (9 g). It is heated
 to reflux, and further (4-bromo-n-butyl)-methyl ether (81.2g)
 is added dropwise, under heating, over 25 minutes.

The reaction mixture is refluxed for 10 minutes, cooled
 20 to 20°C and diluted with THF (390 ml); then cooled further to
 5°C, added with cuprous iodide (5.1 g) and kept 1 hour at
 0-5°C. The mixture is then cooled to -35°C and 7-(5-ketocyclo-
 pentenyl)-heptanoic acid methyl ester (VI, $R'' = Me$) is added
 dropwise thereto.

25 The temperature is allowed to rise spontaneously for 10

minutes. The mixture is poured into water (500 ml). The organic phase is separated, dried and evaporated under reduced pressure, yielding a crude product (84.8 g) which is chromatographed on a silica column to yield the pure title product (64.9 g).

<u>Elemental analysis</u>	<u>Calculated</u>	<u>Found</u>
C	69.18%	69.22%
H	10.32%	10.23%

EXAMPLE 7

9-keto-17-oxa-prostanoic acid of formula (II) wherein R" =H and Y = O.

A methanol (2 ml) solution of NaOH (128.2 mg) is added with the ester obtained in Example 6 dissolved in methanol (1 ml), at ambient temperature, over a period of 5 minutes. The thus obtained solution is left to reflux for 3 hours, cooled, added with water (10 ml) and 1N HCl to pH 1. The reaction mixture is extracted with ether (3 x 100 ml). The ether phase is washed with brine (3 x 10 ml), then brought to pH 3 with 1N HCl.

The organic phase is separated, dried, evaporated under reduced pressure, yielding a crude product (0.41 g) which, after silica chromatography, yields the title acid (0.4 g).

<u>Elemental analysis</u>	<u>Calculated</u>	<u>Found</u>
C	68.42%	68.63%
H	10.13%	10.18%

EXAMPLE 8


Sodium salt of N-acetyl-9-amino-19,20-bis-nor-prostanoic acid
of formula(I), wherein R = H, R' = CH₃CO, Y = CH₂, X = ONa
 (IBI-P-01012)

A solution of the title compound (25 g) of Example 2 (IBI-01009) in DMF (260 ml) is prepared and added, at 0°C, with triethylamine (25.4 g). After 5 minutes stirring, acetyl chloride (9.9 g) is added dropwise. The reaction mixture is left under stirring for 10 minutes, poured into water, and after acidifying with diluted hydrochloric acid, it is extracted with ethyl ether (4 x 400 ml). The thus extracted crude material is purified by silica gel chromatography using diethyl acetate as the eluent. The so-obtained acid (21 g) is dissolved in a NaOH (2.5 g) solution in methanol (37.5 ml). This solution is then concentrated to half its volume at room temperature whereupon it is added with acetonitrile (500 ml). The thus obtained precipitate (18 g) is filtered off.

<u>Elemental analysis</u>	<u>Calculated</u>	<u>Found</u>
C	66.3 %	66.5 %
H	9.9 %	9.8 %
N	4.14%	4.3 %

C L A I M S

1. A compound of formula (I)



wherein

R and R' are the same or different and each represents H, a straight or branched alkyl, alkenyl, alkynyl, (C₁-C₅)-acyl group, -CH₂COOH, -SO₂NH₂, -COCH(NH₂)CH₂SH, or when taken together, they can form a 3 to 8-membered ring, the members of

which can be a carbon atom or a heteroatom such as N, O or S,

X is a hydroxy, (C₁-C₅)-alkoxy, phenoxy, benzyloxy group or NHR'' (wherein R'' is a (C₁-C₅)-alkyl group or H),

Y is =CH₂, ¹CHCH₃, O, S, =NH, -NCH₃,

except when Y is =CH₂, R is H and R' is H or a (C₁-C₄)-alkyl group.

2. A compound of claim 1 wherein X is OH.


3. A compound of claim 2 wherein Y is =CH₂.

4. A compound of claim 3 wherein R = R' = -CH₃.

5. A compound of claim 3 wherein R = H, R' = -COCH₃.

6. a compound of claim 3 wherein R and R' taken together are -CH₂-CH₂-CH₂-CH₂- forming a pyrrolidine heterocycle with the N atom.

7. A compound of claim 2 wherein Y is $\begin{array}{c} \text{CH}_3 \\ | \\ -\text{CH}- \end{array}$.
8. A compound of claim 2 wherein Y is S.
9. A compound of claim 2 wherein Y is O.
10. A process for the preparation of a compound of general formula (I)



wherein

R and R' are the same or different and each represents H, a straight or branched alkyl, alkenyl, alkynyl, (C_1-C_5) -acyl group, $-\text{CH}_2\text{COOH}$, $-\text{SO}_2\text{NH}_2$, $\text{COCH}(\text{NH}_2)\text{CH}_2\text{SH}$, or when taken together, they can form a 3 to 8-membered ring, the members of which can be a carbon atom or a heteroatom such as N, O or S,


X is a hydroxy, (C_1-C_5) -alkoxy, phenoxy, benzyloxy group, or NHR'' (wherein R'' is a (C_1-C_5) -alkyl group or H),

Y is $=\text{CH}_2$, CHCH_3 , O, S, $=\text{NH}$, $-\text{NCH}_3$,

characterized by performing a reductive amination of a ketone of general formula (II) in a polar solvent, at a temperature of between 20°C to reflux, in an atmosphere of hydrogen (hydrogen pressure of from 1 to 10 atmospheres), in the presence of a metal catalyst, and in the presence of the appropriate $\text{RR}'\text{NH}$ amine.

11. A process for the preparation of a compound of general formula (I) of claim 10 wherein $R = R' = H$, characterized by first preparing an oxime of general formula (III) by reacting a ketone of general formula (II) with hydroxylamine in a polar solvent, in the presence of a buffer, at a temperature of from 20° to reflux, and subsequently by reducing the oxime in an atmosphere of hydrogen, at a pressure of from 1 to 10 atmospheres, and in the presence of a metal catalyst.

12. A compound of general formula (II) wherein Y is $\begin{smallmatrix} \text{CH}_3 \\ | \\ -\text{CH}- \end{smallmatrix}$, O, S, =NH, $-\text{NCH}_3$



and wherein R''' is H or a straight or branched (C_1-C_5) -alkyl group.

13. A process for the preparation of a compound of formula (II) of claim 12, characterized by the fact that an addition reaction is carried out using a Grignard reagent in an ether solvent, at a temperature of from -80 to $+20^{\circ}\text{C}$, in the presence of a copper salt, using as the substrate a compound of general formula (IV).


14. A pharmaceutical composition having antiulcer activity containing a compound of general formula (I) of claim 10, or a pharmaceutically acceptable salt thereof, and at least

one pharmaceutically acceptable vehicle or excipient.

15. A pharmaceutical composition having anorectic activity containing a compound of general formula (I) of claim 10 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable vehicle or excipient.

C L A I M S F O R A U S T R I A

1 1. A process for the preparation of a compound of general
formula (I)



wherein

R and R' are the same or different and each represents H, a
straight or branched alkyl, alkenyl, alkynyl, (C₁-C₅)-acyl
10 group, -CH₂COOH, -SO₂NH₂, COCH(NH₂)CH₂SH, or when taken toge-
ther, they can form a 3 to 8-membered ring, the members of
which can be a carbon atom or a heteroatom such as N, O or S,
X is a hydroxy, (C₁-C₅)-alkoxy, phenoxy, benzyloxy group, or
NHR'' (wherein R'' is a (C₁-C₅)-alkyl group or H),


15 Y is =CH₂, CHCH₃, O, S, =NH, -NCH₃,

characterized by performing a reductive amination of a ketone
of general formula (II) in a polar solvent, at a temperature
of between 20°C to reflux, in an atmosphere of hydrogen (hy-
drogen pressure of from 1 to 10 atmospheres), in the presence
20 of a metal catalyst, and in the presence of the appropriate
RR'NH amine.

2. A process for the preparation of a compound of gen-
eral formula (I) of claim 1 wherein R = R' = H, characterized
by first preparing an oxime of general formula (III) by

reacting a ketone of general formula (II) with hydroxylamine in a polar solvent, in the presence of a buffer, at a temperature of from 20°C to reflux, and subsequently reducing the oxime in an atmosphere of hydrogen, at a pressure of from 1 to 10 atmospheres, and in the presence of a metal catalyst.

3. A process for the preparation of a compound of formula (II)



wherein Y is $-\overset{\text{CH}_3}{\underset{|}{\text{CH}}}-$, O, S, =NH, -NCH₃ and wherein R''' is H or a straight or branched (C₁ -C₅) -alkyl group characterized by the fact that an addition reaction is carried out using a Grignard reagent in an ether solvent, at a temperature of from -80 to +20°C, in the presence of a copper salt, using as the substrate a compound of general formula (IV).

4. A process for making a pharmaceutical composition having antiulcer activity characterized in that a compound of general formula (I) of claim 1, or a pharmaceutically acceptable salt thereof, is admixed with at least one pharmaceutically acceptable vehicle or excipient.

5. A process for making a pharmaceutical composition having anorectic activity characterized in that a compound of general formula (I) of claim 1, or a pharmaceutically acceptable salt thereof, is admixed with at least one pharmaceutically acceptable vehicle or excipient.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.